GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AB Science (CHIX:ABp) » Definitions » Float Percentage Of Total Shares Outstanding

AB Science (CHIX:ABP) Float Percentage Of Total Shares Outstanding : 0.00% (As of Jun. 06, 2024)


View and export this data going back to 2012. Start your Free Trial

What is AB Science Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, AB Science's float shares is 0.00 Mil. AB Science's total shares outstanding is 52.07 Mil. AB Science's float percentage of total shares outstanding is 0.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, AB Science's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, AB Science's Institutional Ownership is 1.04%.


AB Science Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

AB Science's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=0.00/52.07
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AB Science (CHIX:ABP) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AB Science (CHIX:ABp) » Definitions » Float Percentage Of Total Shares Outstanding
Traded in Other Exchanges
Address
3, Avenue George V, Paris, FRA, 75008
AB Science is a France-based pharmaceutical company specialized in the research, discovery, development, and marketing of protein kinase inhibitors. It is engaged in targeted therapies through tyrosine kinase inhibitors for treating diseases with high medical factor in the field of cancer, chronic inflammatory diseases, neurological degenerative disorders and central nervous systems diseases in both human and veterinary medicine.

AB Science (CHIX:ABP) Headlines